XML 40 R28.htm IDEA: XBRL DOCUMENT v3.25.1
Segment Reporting (Tables)
12 Months Ended
Dec. 31, 2024
Segment Reporting  
SUMMARY OF SIGNIFICANT EXPENSE CATEGORIES FOR THE SEGMENT

    

Years ended December 31,

    

2024

    

2023

Operating expenses:

AV-101 clinical trials

$

19,740

$

26,548

Employee costs

19,512

21,244

Professional fees and services

11,482

6,289

Stock-based compensation

11,311

11,906

Chemistry, manufacturing, and controls

11,110

14,339

Other segment items(a)

1,515

1,140

Interest income

(5,042)

(5,945)

Consolidated net loss

$

69,628

$

75,521

(a) Other segment items include rent and facilities related expenses.